- Oops!Something went wrong.Please try again later.
The drug, Nuplazid, is already indicated for Parkinson's-related psychosis.
Acadia tried and failed last year to get another FDA approval for Alzheimer's psychosis.
"We are disappointed with the outcome of today's vote. We will continue to work closely with the FDA as it completes its review of the totality of our efficacy and safety data to enable a full assessment of pimavanserin's benefit-risk in patients with ADP," said Steve Davis, CEO.
Pimavanserin has slogged through a rough journey, with a late-stage fail in trials of patients with major depressive disorder in July 2020 and Phase 3 disappointment in schizophrenia patients in 2019.
HC Wainwright & Co maintains Acadia with a Buy and lowers the price target from $36 to $20.
RBC Capital analyst keeps the rating unchanged at Outperform but lowers the price target from $32 to $26.
Price Action: ACAD shares are down 31.42% at $13.38 during the premarket session on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.